Science Hub is Novo Nordisk’s one-stop portal for all our scientific publications and clinical trials, congress materials and medical updates. Sign up to gain full access.
Academy for Sickle Cell and Thalassaemia (ASCAT 2026)7 - 10 October 2026
Etavopivat improves hemoglobin levels in adults and adolescents with non-transfusion-dependent α- or β-thalassaemia: results from the open-label phase 2 gladiolus study
Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.